Virtuix Partners with Sirica Therapeutics for AI-Driven Autism Therapy, Targets 100 Treatment Centers
VTIX sits 24% above its 52-week low of $2.57 on light trading volume (0.3× avg).
Summary
Virtuix has signed a strategic partnership with Sirica Therapeutics to deploy its Omni One VR platform for AI-driven autism therapy. The company has already sold and shipped the first two Omni One systems to Sirica's initial treatment center. This collaboration is significant as Sirica Therapeutics plans to establish approximately 100 autism treatment centers nationwide, representing a substantial potential expansion for Virtuix into the healthcare market. This move diversifies Virtuix's revenue streams beyond its existing defense and consumer applications, following recent positive financial results but also ongoing needs for funding.
At the time of this announcement, VTIX was trading at $3.19 on NASDAQ in the Technology sector, with a market capitalization of approximately $103M. The 52-week trading range was $2.57 to $92.74. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.